Long-term adherence to a 5 day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1688-1694

  Edgeworth, Jonathan D ^a   Ster, Irina Chis ^a   Wyncoll, Duncan ^a   Shankar Hari, Manu ^a   McKenzie, Catherine A ^b,c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aminoglycosides; Antibiotic resistance; Gram negative bacteria

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; RESPIRATORY SYSTEM; CROSS INFECTION; DRUG COMBINATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GUIDELINE ADHERENCE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903897709     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku038     Document Type: Article

References (39)

1. Hanberger H, Arman D, Gill H et al. Surveillance of microbial resistance in European intensive care units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009; 35: 91-100.
2. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011; 1: 47.
3. Kaki R, Elligsen M, Walker S et al. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011; 66: 1223-30.
4. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42 Suppl 2: S72-81.
5. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
6. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
7. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-23.
8. Leibovici L, Drucker M, Konigsberger H et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis 1997; 29: 71-5.
9. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-48.
10. Valles J, Rello J, Ochagavia A et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-4.
11. Zaragoza R, Artero A, Camarena JJ et al. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9: 412-8.
12. Pena C, Gudiol C, Calatayud L et al. Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect 2008; 68: 116-22.
13. Corona A, Bertolini G, Lipman J et al. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65: 1276-85.
14. Hranjec T, Rosenberger LH, Swenson B et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 2012; 12: 774-80.
15. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005; 171: 388-416.
16. Torres A, Ewig S, Lode H et al. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009; 35: 9-29. 17. Masterton RG, Galloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62: 5-34.
17. Masterton RG, Galloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62: 5-34.
18. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilatorassociated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-95.
19. Heyland DK, Dodek P, Muscedere J et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 737-4.
20. Kett DH, Cano E, Quartin AA et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011; 11: 181-9.
21. Kumar A, Zarychanski R, Light B et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-85.
22. Kumar A, Safdar N, Kethireddy S et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38: 1651-64.
23. Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005; 128: 940-6.
24. Ewig S. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis 2011; 11: 155-7.
25. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
26. Heenen S, Jacobs F, Vincent JL. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often?. Crit Care Med 2012; 40: 1404-9.
27. Mermel LA, Allon M, Bouza E. Clinical practice guidelines for the diagnosis and management of intravascular catheter related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
28. Malacarne P, Rossi C, Bertolini G. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother 2004; 54: 221-4.
29. Bergmans DC, Bonten MJ, Gaillard CA et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 1997; 39: 527-35.
30. Corona A, Bertolini G, Ricotta AM et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother 2003; 52: 849-52.
31. Corona A, Wilson AP, Grassi M et al. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother 2004; 54: 809-17.
32. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27: 1421-8.
33. Vlek AL, Cooper BS, Kypraios T et al. Clustering of antimicrobial resistance outbreaks across bacterial species in the intensive care unit. Clin Infect Dis 2013; 57: 65-76.
34. Simes RJ. An improved Bonferroni procedure for multiple test of significance. Biometrika 1986; 73: 751-4.
35. Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. Newsletter of the British Society for Antimicrobial Chemotherapy. Summer 1998; 1-30.
36. Chastre J, WolffM, Fagon FY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-98.
37. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32-48.
38. Panidis D, Markantonis SL, Boutzouka E et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128: 545-52.
39. Craig WA. Gentamicin. In: Grayson ML, Crowe SM, McCarthy JS et al., eds. Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. London: Edward Arnold, 2010; 674-98.